Preeclampsia Clinical Trial
— earlyGRAFDOfficial title:
Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler (Early GRAFD)
This is a multicentre, open-label, randomized controlled trial. A total of 340 singleton pregnancies with an EFW ≤10th percentile between 26+0 and 31+6 weeks will be recruited and randomly allocated to either the control or the intervention group. In the control group, standard Doppler-based management will be used. In the intervention group, different soluble fms-like tyrosine kinase to placental growth factor ratio (sFlt-1/PlGF) cutoffs will be incorporated to the current protocol to adjust the frequency of ultrasounds and to plan elective delivery.
Status | Not yet recruiting |
Enrollment | 340 |
Est. completion date | December 30, 2026 |
Est. primary completion date | September 1, 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Pregnant women of at least 18 years old - Singleton pregnancy - Ultrasonographic EFW =10th percentile between 26+0 and 31+6 weeks of gestation - Gestational age confirmed by fetal crown-rump length measurement during the first trimester scan (from 11+0 to 13+6 weeks of gestation) or by in vitro fertilization dates. Exclusion Criteria: - Major fetal malformations or genetic disorders - Fetal death - Refusal to give informed consent - Stage IV FGR |
Country | Name | City | State |
---|---|---|---|
Spain | Complejo Hospitalario Universitario de A Coruña | A Coruña | |
Spain | Hospital Universitario General de Alicante | Alicante | |
Spain | Hospital Universitari Germans Trias i Pujol | Badalona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital Universitari Dexeus | Barcelona | |
Spain | Vall d'hebron Barcelona Hospital Campus | Barcelona | |
Spain | Hospital Universitario Puerta del Mar | Cadiz | |
Spain | Hospital General Universitario de Elche | Elche | |
Spain | Hospital Universitario de Getafe | Getafe | |
Spain | Hospital Universitario de Cabueñes | Gijón | |
Spain | Hospital Universitari de Girona Doctor Josep Trueta | Girona | |
Spain | Hospital Universitario San Cecilio | Granada | |
Spain | Hospital Universitario de Jerez de la Frontera | Jerez De La Frontera | |
Spain | Hospital Materno Infantil de Gran Canaria | Las Palmas De Gran Canaria | |
Spain | Hospital Universitari Arnau de Vilanova | Lleida | |
Spain | Hospital Clínico San Carlos | Madrid | |
Spain | Hospital Universitari Son Espases | Palma De Mallorca | |
Spain | Hospital Universitari Son Llàtzer | Palma De Mallorca | |
Spain | Corporació Sanitària Parc Taulí | Sabadell | |
Spain | Hospital Universitario de Canarias | Santa Cruz De Tenerife | |
Spain | Hospital Universitario Virgen de Valme | Sevilla | |
Spain | Virgen Macarena | Sevilla | |
Spain | Hospital Universitario Joan XXIII de Tarragona | Tarragona | |
Spain | Consorci Sanitari de Terrassa | Terrassa | |
Spain | Hospital Universitari Mútua Terrassa | Terrassa | |
Spain | Hospital Universitario de Torrejón | Torrejón De Ardoz | |
Spain | Hospital Clínico Universitario Lozano Blesa | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Hospital Universitari Vall d'Hebron Research Institute | Instituto de Salud Carlos III, Roche Diagnostics GmbH |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fetal and Neonatal complications | stillbirth, neonatal death, artery cord pH =7.0, respiratory distress syndrome, required invasive ventilatory support, grade III or IV intraventricular hemorrhage, neonatal sepsis, necrotizing enterocolitis, neonatal seizures, pneumonia, meningitis, broncopulmonary dysplasia, hypoxic ischemic encephalopathy, Apgar score <7 at 5 minutes, or elective delivery at <28 weeks of gestation. | During pregnancy and up to 28 days after delivery | |
Primary | Composite adverse maternal outcome | Progression to PE with severity features; progression to hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome (LDH >600 IU/L, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevated more than twice the upper limit of normal, and the platelet count less than 100 X 109/L); eclampsia, stroke, hepatic hematoma or rupture; oliguria (urine output of <400 mL during 24 hours, or need for treatment with furosemide to maintain urine output at >400 mL for 24 hours); cardiovascular dysfunction (need for inotropic support, left ventricle failure, or myocardial infarction); placental abruption; maternal death; maternal admission to intensive care unit >48 hours, and/or requirement for blood transfusion. | During pregnancy and up to 28 days after delivery | |
Secondary | Maternal perceived stress | Mean and sd or median and IQR of the score obtained in the perceived stress scale in each group | At inclusion and 4 weeks later | |
Secondary | Other perinatal outcomes | transient tachypnea, non-invasive ventilatory support, hypoglycemia, neonatal jaundice (treated with phototherapy), rate of elective deliveries < 30 weeks, <34 weeks and < 37 weeks for FGR and/or PE, birthweight <3 rd and <10th percentiles, mode of delivery (vaginal, instrumental vaginal delivery and Cesarean), rate of Cesarean delivery for abnormal CTG, median maternal stay in ICU, median neonatal stay in N-ICU, maternal corticosteroids (single dose, complete course), prenatal magnesium sulfate (at least 4h) for preterm delivery. | During pregnancy and up to 28 days after delivery | |
Secondary | Number of ultrasounds per participant | Mean and sd or median and IQR in each group | During pregnancy (before and after 37 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |